More studies on hydroxychloroquine - flu mortality 2-5 times lower

.

1. FIVE TIMES LOWER MORTALITY

"COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study", by Martin Scholz * , Roland Derwand , Vladimir Zelenko,
Version 1, Published Online: 3 July 2020

Abstract
Objective: To describe outcomes of patients with coronavirus disease 2019 (COVID-19) in the outpatient setting after early treatment with zinc, low dose hydroxychloroquine, and azithromycin (the triple therapy) dependent on risk stratification. Design: Retrospective case series study. Setting: General practice. Participants: 141 COVID-19 patients with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the year 2020. Main Outcome Measures: Risk-stratified treatment decision, rate of hospitalization and all-cause death. Results: Of 335 positively PCR-tested COVID-19 patients, 127 were treated with the triple therapy. 104 of 127 met the defined risk stratification criteria and were included in the analysis. In addition, 37 treated and eligible patients who were confirmed by IgG tests were included in the treatment group (total N=141). 208 of the 335 patients did not meet the risk stratification criteria and were not treated. After 4 days (median, IQR 3-6, available for N=66/141) of onset of symptoms, 141 patients (median age 58 years, IQR 40-60; 73% male) got a prescription for the triple therapy for 5 days. Independent public reference data from 377 confirmed COVID-19 patients of the same community were used as untreated control. 4 of 141 treated patients (2.8%) were hospitalized, which was significantly less (p less than 0.001) compared with 58 of 377 untreated patients (15.4%) (odds ratio 0.16, 95% CI 0.06-0.5). Therefore, the odds of hospitalization of treated patients were 84% less than in the untreated group. One patient (0.7%) died in the treatment group versus 13 patients (3.5%) in the untreated group (odds ratio 0.2, 95% CI 0.03-1.5; p=0.16). There were no cardiac side effects. Conclusions: Risk stratification-based treatment of COVID-19 outpatients as early as possible after symptom onset with the used triple therapy, including the combination of zinc with low dose hydroxychloroquine, was associated with significantly less hospitalizations and 5 times less all-cause deaths.

2. MORTALITY HALVED

"Study finds hydroxychloroquine may have boosted survival, but other researchers have doubts", By Maggie Fox, Andrea Kane, and Elizabeth Cohen, CNN
Updated 1:31 PM ET, Fri July 3, 2020

(new link to Ford Study)


Quote:

(CNN)A surprising new study found the controversial antimalarial drug hydroxychloroquine helped patients better survive in the hospital. But the findings, like the federal government's use of the drug itself, were disputed.

A team at Henry Ford Health System in southeast Michigan said Thursday their study of 2,541 hospitalized patients found that those given hydroxychloroquine were much less likely to die.

Dr. Marcus Zervos, division head of infectious disease for Henry Ford Health System, said 26% of those not given hydroxychloroquine died, compared to 13% of those who got the drug. The team looked back at everyone treated in the hospital system since the first patient in March.
"Overall crude mortality rates were 18.1% in the entire cohort, 13.5% in the hydroxychloroquine alone group, 20.1% among those receiving hydroxychloroquine plus azithromycin, 22.4% among the azithromycin alone group, and 26.4% for neither drug," the team wrote in a report published in the International Journal of Infectious Diseases.

...

It's a surprising finding because several other studies have found no benefit from hydroxychloroquine, a drug originally developed to treat and prevent malaria. President Donald Trump touted the drug heavily, but later studies found not only did patients not do better if they got the drug, they were more likely to suffer cardiac side effects....

Comment (by Heretic): some of those negative studies that resulted in governments of many countries and WHO abandoning this line of therapies, most notably the one published recently by The Lancet were based on fraud and has since been recalled. (P.S., CNN - "purveyors of fake news" as they say, when I find a more credible link I will post it, but for now, sorry...)

------------------ Follow up story (5-July-2020 -------------------------

Medical establishment has been recently attempting to suppress a common drug against the recent flu outbreak. The drug that was recommended by the US president - hydroxychloroquine. The suppression involved publishing a completely fabricated negative trial paper using fraudulent data (see the recently super-quickly published and equally quickly retracted Lancet paper) while promoting some alternative drugs and hypothetical (future) vaccines by the top US health official Dr. Fauci.

One of such drug is Remdesivir produced by Gilead Sciences. Now it turns out that Remdesivir seems to be ineffective, see below:

... and the company or their backers in the medical establishment attempted to cover it up:

... but there are also some new doubts cast on the Remdesivir trial conducted by Dr. Fauci's company itself.

One such doubt is the trial specification removing "Death" from the set of sought outcomes.

At the same time, the two recently disclosed or published studies on hydroxychloroquine showed dramatic and positive outcome on patients' recovery. As you can see in the original section posted above. For example mortality reductions by 2 to 5 times!

So it turns out, the president of the United states was correct while his top medical advisor was wrong (at best) or may even end up proven malfaisant in the future.

Youtube video:

"BREAKING: REMDESIVIR STUDY MANIPULATED?",

posted May 4, 2020

by "The HighWire with Del Bigtree"

(Note: I recommend watching it soon, it might not remain for very long!)
Update 1-Aug-2020 - Youtube just "torched"  Dell Bigtree's account last week!  I hope He Will be Back!

------------------- Update 07/07/2020 ------------------

3. FIVE TIMES (1/0.18) LOWER RISK OF TRANSFER TO INTENSIVE CARE OR DEATH

"Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis", by Jean-Christophe Lagier et al., Travel Medicine and Infectious Disease, 25 June 2020, 101791

Quote:

...Treatment with HCQ-AZ was associated with a decreased risk of transfer to ICU or death (Hazard ratio (HR) 0.18 0.11–0.27), decreased risk of hospitalization ≥10 days (odds ratios 95% CI 0.38 0.27–0.54) and shorter duration of viral shedding (time to negative PCR: HR 1.29 1.17–1.42). QTc prolongation (greater than 60 ms) was observed in 25 patients (0.67%) leading to the cessation of treatment in 12 cases including 3 cases with QTc greater than 500 ms. No cases of torsade de pointe or sudden death were observed.

Conclusion
Although this is a retrospective analysis, results suggest that early diagnosis, early isolation and early treatment of COVID-19 patients, with at least 3 days of HCQ-AZ lead to a significantly better clinical outcome and a faster viral load reduction than other treatments.

----------------- Update 1/08/2020 ----------------------

FDA Hydroxychloroquine Ban, Fake Science, And Political Agendas,
Have COVID-19 patients been given lethal doses of hydroxychloroquine to discredit its efficacy?
By: Pennel BirdJune 21, 2020Articles, Healthcare, Ignored by MSM, Politics

Quote:

Studies Designed To Fail

As Doctor Jim Meehan conjectures, these studies are designed to fail. He believes this is being done to contrive a message to manipulate, mislead and deceive the masses, and that public health is being subverted by commercial bias and political agendas. ...

And these excessive doses are not only making it impossible to assess the therapeutic benefits of HCQ for COVID-19 patients accurately. They are clearly hastening the deaths of many in the study who have been unaccountably administered dangerous amounts of a highly effective drug with a 70-year record of safety and efficacy. A highly salient point made by Del Bigtree of ICAN is that well over 5 million doses of hydroxychloroquine were taken in the United States in 2107 [2017?] for the treatment of lupus, arthritis, and malaria. If the FDA is so concerned about adverse effects associated with HCQ, why wait until now to revoke its use when it was used so widely and so effectively just a few years ago? ...

------------------ Update 9-Aug-2020 --------------

 List of 70 studies (42 peer-reviewed) on Covid-19 treatment using Hydrochloroquine and other. 

  Global HCQ studies. PrEP, PEP, and early treatment studies show high effectiveness, while late treatment shows mixed results.

--------------------- Update 1-Sep-2020 ----------------------------------
Link to the article: "Covid Analysis" This is a compilation of 84 published studies, 49 of them peer-reviewed (all referenced and linked):



Covid Analysis

----------------- Update 21-Oct-2020 ----------------------------
Dubee et al., medRxiv, doi:10.1101/2020.10.19.20214940 (Preprint), "A placebo-controlled double blind trial of hydroxychloroquine in mild-to-moderate COVID-19"

Small early terminated late stage (60% on oxygen) RCT in France showing 46% lower mortality. mortality at 28 days relative risk RR 0.54 [0.21-1.42] combined mortality/intubation at 28 days relative risk RR 0.74 [0.33-1.70]

----------------- Update 25 Nov 2020 -------------------------------
"Study finds 84% fewer hospitalizations for patients treated with controversial drug hydroxychloroquine", by Andrew Mark Miller, Social Media Producer, November 25, 2020

Nail to the coffin of prof Campbell's theory of cancer supposedly triggered by protein

.

A long-time vegan diet promoter Prof-emeritus T.C Campbell of Cornell University, author of The China Study book, used to claim in his studies that adding protein to high carbohydrate mice diet does trigger the cancer while removing it reduces the frequency and size of cancerous tumors. Campbell argues that casein, a protein found in milk from mammals, is "the most significant carcinogen we consume" (see Wiki T. Colin Campbell and Talk by T. Colin Campbell Archived 2011-04-17 at the Wayback Machine, Google Videos, 20:24 mins, accessed December 3, 2010.).

Campbell's theory has been questioned for some time. Most notably, Denise Minger has posted some very in-depth and thorough analyses on-line discussing what exactly may have gone wrong with Campbell's research.

This study found that the reality is in fact quite the opposite to the scientist's claim, showing that a high protein low carbohydrate diet had in fact almost completely protected the genetically-modified cancer-susceptible mice against getting cancer (while the high-carbohydrate control group got 50% cancer!)

"A Low Carbohydrate, High Protein Diet Slows Tumor Growth and Prevents Cancer Initiation", by
Victor W. Ho, Kelvin Leung, Anderson Hsu, Beryl Luk, June Lai, Sung Yuan Shen, Andrew I. Minchinton, Dawn Waterhouse, Marcel B. Bally, Wendy Lin, Brad H. Nelson, Laura M. Sly and Gerald Krystal, Published in Cancer Research/AACR, July 2011


Quote

Abstract

Since cancer cells depend on glucose more than normal cells, we compared the effects of low carbohydrate (CHO) diets to a Western diet on the growth rate of tumors in mice. To avoid caloric restriction–induced effects, we designed the low CHO diets isocaloric with the Western diet by increasing protein rather than fat levels because of the reported tumor-promoting effects of high fat and the immune-stimulating effects of high protein. We found that both murine and human carcinomas grew slower in mice on diets containing low amylose CHO and high protein compared with a Western diet characterized by relatively high CHO and low protein. There was no weight difference between the tumor-bearing mice on the low CHO or Western diets.

Additionally, the low CHO-fed mice exhibited lower blood glucose, insulin, and lactate levels. Additive antitumor effects with the low CHO diets were observed with the mTOR inhibitor CCI-779 and especially with the COX-2 inhibitor Celebrex, a potent anti-inflammatory drug. Strikingly, in a genetically engineered mouse model of HER-2/neu–induced mammary cancer, tumor penetrance in mice on a Western diet was nearly 50% by the age of 1 year whereas no tumors were detected in mice on the low CHO diet. This difference was associated with weight gains in mice on the Western diet not observed in mice on the low CHO diet. Moreover, whereas only 1 mouse on the Western diet achieved a normal life span, due to cancer-associated deaths, more than 50% of the mice on the low CHO diet reached or exceeded the normal life span. Taken together, our findings offer a compelling preclinical illustration of the ability of a low CHO diet in not only restricting weight gain but also cancer development and progression. Cancer Res; 71(13); 4484–93. ©2011 AACR.

What was also interesting that an addition of an anti-inflammatory COX-2 inhibitor drug (Celebrex, 1g/kg body) slowed down the tumor growth by about a half, regardless of a diet! Not sure how to interpret it, perhaps that inflammation accelerates the tumor growth in general?